Sorapinib Receives Orphan Drug Designation from the U.S. FDA
October 29, 2026
Source: drugdu
35
Nanfang Daily News, October 29th – Hutchison MediPharma (00013.HK) issued a voluntary announcement stating that its sorbipinib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary immune thrombocytopenic purpura (PETP). Solepinib is a novel, highly selective oral spleen tyrosine kinase inhibitor. If approved, the drug will be eligible for seven years of market exclusivity in the U.S. from the date of approval, and will be eligible for various development incentives, including tax credits. In addition, two new drug applications for sorbipinib in China, for the treatment of PETP and warm antibody-type autoimmune hemolytic anemia, are currently under review.
Source: https://finance.eastmoney.com/a/202610293913017516.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting October 29, 2026
- Chipscreen’s NW001, the World’s First Epigenetic Immune-Modulating Antibody Conjugate, Approved for Clinical Trials October 29, 2026
- Dongyangguang Pharmaceutical aims to be the first generic drug. October 29, 2026
- Following a collective trading halt, MicroPort Medical officially announced a change in leadership! October 29, 2026
- What new growth signals did Hengrui Medicine release in the third quarter? October 29, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
